Chinese General Practice ›› 2023, Vol. 26 ›› Issue (26): 3220-3229.DOI: 10.12114/j.issn.1007-9572.2023.0156
• Evidence-based Medicine • Previous Articles Next Articles
Received:
2023-03-13
Revised:
2023-04-25
Published:
2023-09-15
Online:
2023-05-05
Contact:
SU Guobin, LU Fuhua
About author:
通讯作者:
苏国彬, 卢富华
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0156
药物 | 肌酐清除率(CrCl)>50 mL/min | CrCl 10~50 mL/min | CrCl<10 mL/min | 透析 |
---|---|---|---|---|
常用解热药 | ||||
对乙酰氨基酚 | 每次给药间隔至少4 h以上 | 每次给药间隔6 h以上,定期监测肾功能 | 每次给药间隔8 h以上,定期监测肾功能 | 血液透析、腹膜透析(CAPD)模式和连续肾脏替代疗法(CRRT)均不主张透析后额外补充给药 |
布洛芬a[ | 一般情况下单次给药剂量无需调整,连续使用≤2 d | |||
中成药 | 尚缺乏清肺排毒颗粒、藿香正气胶囊(软胶囊、丸、水、口服液)、疏风解毒胶囊(颗粒)、化湿败毒颗粒、宣肺败毒颗粒、散寒化湿颗粒、金花清感颗粒、连花清瘟胶囊(颗粒)等推荐中成药在CKD人群中的药物剂量调整数据。 | |||
止咳化痰药[ | ||||
溴己新 | 可选用,严重肝肾功能损伤时,溴己新代谢产物的清除率降低,说明书未提供具体调整方法 | |||
乙酰半胱氨酸 | 可选用,口服t1/2 6.25 h,肾脏清除率占总清除率30%,说明书未提供具体调整方法 | |||
氨溴索 | 可选用,t1/2约10 h,肾脏清除率占总清除率83%,肾功能不全者减量或延长两次给药间隔时间 | |||
愈创甘油醚 | 肾炎及肾功能受损者禁用 | |||
氯化铵 | 肾功能不全禁用铵盐,代谢性酸中毒禁用 | |||
右美沙芬 | 中枢性镇咳药,原型及代谢物主要经肾脏排泄,肾功能不全者慎用 | |||
福尔可定 | 仅供二线使用,严重肾功能受损时需调整剂量,说明书未提供具体调整方法 | |||
抗过敏药[ | ||||
苯海拉明 | 25~50 mg口服,给药间隔4~6 h;最大剂量≤300 mg/d | 25~50 mg口服,给药间隔延长至6~12 h;最大剂量≤300 mg/d | 25~50 mg口服,给药间隔延长至12~18 h;最大剂量≤300 mg/d | 血液透析、CAPD模式和CRRT均不主张透析后额外补充给药 |
氯苯那敏 | 每次4 mg口服,给药间隔4~6 h | 血液透析后无需额外补充,CAPD模式中疗效不明确,CRRT中无效 | ||
氯雷他定 | 10 mg/次,1次/d,使用过程注意监测不良反应和肾功能水平 | |||
西替利嗪 | 10 mg/次、1次/d;或5 mg/次、早晚各1次;或遵医嘱 | 5 mg/次、1次/d |
Table 1 Dose adjustment table for symptomatic treatment of COVID-19 infection in chronic kidney disease patients with different kidney function levels
药物 | 肌酐清除率(CrCl)>50 mL/min | CrCl 10~50 mL/min | CrCl<10 mL/min | 透析 |
---|---|---|---|---|
常用解热药 | ||||
对乙酰氨基酚 | 每次给药间隔至少4 h以上 | 每次给药间隔6 h以上,定期监测肾功能 | 每次给药间隔8 h以上,定期监测肾功能 | 血液透析、腹膜透析(CAPD)模式和连续肾脏替代疗法(CRRT)均不主张透析后额外补充给药 |
布洛芬a[ | 一般情况下单次给药剂量无需调整,连续使用≤2 d | |||
中成药 | 尚缺乏清肺排毒颗粒、藿香正气胶囊(软胶囊、丸、水、口服液)、疏风解毒胶囊(颗粒)、化湿败毒颗粒、宣肺败毒颗粒、散寒化湿颗粒、金花清感颗粒、连花清瘟胶囊(颗粒)等推荐中成药在CKD人群中的药物剂量调整数据。 | |||
止咳化痰药[ | ||||
溴己新 | 可选用,严重肝肾功能损伤时,溴己新代谢产物的清除率降低,说明书未提供具体调整方法 | |||
乙酰半胱氨酸 | 可选用,口服t1/2 6.25 h,肾脏清除率占总清除率30%,说明书未提供具体调整方法 | |||
氨溴索 | 可选用,t1/2约10 h,肾脏清除率占总清除率83%,肾功能不全者减量或延长两次给药间隔时间 | |||
愈创甘油醚 | 肾炎及肾功能受损者禁用 | |||
氯化铵 | 肾功能不全禁用铵盐,代谢性酸中毒禁用 | |||
右美沙芬 | 中枢性镇咳药,原型及代谢物主要经肾脏排泄,肾功能不全者慎用 | |||
福尔可定 | 仅供二线使用,严重肾功能受损时需调整剂量,说明书未提供具体调整方法 | |||
抗过敏药[ | ||||
苯海拉明 | 25~50 mg口服,给药间隔4~6 h;最大剂量≤300 mg/d | 25~50 mg口服,给药间隔延长至6~12 h;最大剂量≤300 mg/d | 25~50 mg口服,给药间隔延长至12~18 h;最大剂量≤300 mg/d | 血液透析、CAPD模式和CRRT均不主张透析后额外补充给药 |
氯苯那敏 | 每次4 mg口服,给药间隔4~6 h | 血液透析后无需额外补充,CAPD模式中疗效不明确,CRRT中无效 | ||
氯雷他定 | 10 mg/次,1次/d,使用过程注意监测不良反应和肾功能水平 | |||
西替利嗪 | 10 mg/次、1次/d;或5 mg/次、早晚各1次;或遵医嘱 | 5 mg/次、1次/d |
药物 | 估算肾小球滤过率(eGFR)≥60 mL·min-1·(1.73 m2)-1 | eGFR 30~59 mL·min-1·(1.73 m2)-1 | eGFR 15~29 mL·min-1·(1.73 m2)-1 | eGFR<15 mL·min-1·(1.73 m2)-1 | 透析 |
---|---|---|---|---|---|
瑞德西韦[ | 第1天:200 mg、1次/d,静脉滴注;第2~5天:100 mg、1次/d,静脉滴注(若临床表现未改善,或为维持机械通气或体外膜肺氧合治疗,疗程延长至10 d) | 不建议使用 | |||
奈玛特韦/利托那韦[ | 奈玛特韦300 mg+利托那韦100 mg、1次/12 h,口服;总疗程5 d | 奈玛特韦150 mg+利托那韦100 mg、1次/12 h,口服[ | 因缺乏数据,说明书中不推荐使用,确有需求者充分知情后建议采用减量方案:第1天:奈玛特韦300 mg+利托那韦100 mg、1次/24 h,口服;第2~5天:奈玛特韦150 mg+利托那韦100 mg、1次/24 h,口服[ | ||
莫诺拉韦[ | 800 mg、1次/12 h,口服,连续使用5 d | ||||
阿兹夫定[ | 5 mg、1次/d,口服,疗程≤14 d | 中重度肾功能损伤慎用 | |||
氢溴酸氘瑞米德韦(VV116)[ | 第1天:600 mg、1次/12 h,口服;第2~5天:300 mg、1次/12 h,口服 | 暂无研究数据 |
Table 2 Recommended dose table of antiviral drugs after COVID-19 infection in chronic kidney disease patients with different kidney function levels
药物 | 估算肾小球滤过率(eGFR)≥60 mL·min-1·(1.73 m2)-1 | eGFR 30~59 mL·min-1·(1.73 m2)-1 | eGFR 15~29 mL·min-1·(1.73 m2)-1 | eGFR<15 mL·min-1·(1.73 m2)-1 | 透析 |
---|---|---|---|---|---|
瑞德西韦[ | 第1天:200 mg、1次/d,静脉滴注;第2~5天:100 mg、1次/d,静脉滴注(若临床表现未改善,或为维持机械通气或体外膜肺氧合治疗,疗程延长至10 d) | 不建议使用 | |||
奈玛特韦/利托那韦[ | 奈玛特韦300 mg+利托那韦100 mg、1次/12 h,口服;总疗程5 d | 奈玛特韦150 mg+利托那韦100 mg、1次/12 h,口服[ | 因缺乏数据,说明书中不推荐使用,确有需求者充分知情后建议采用减量方案:第1天:奈玛特韦300 mg+利托那韦100 mg、1次/24 h,口服;第2~5天:奈玛特韦150 mg+利托那韦100 mg、1次/24 h,口服[ | ||
莫诺拉韦[ | 800 mg、1次/12 h,口服,连续使用5 d | ||||
阿兹夫定[ | 5 mg、1次/d,口服,疗程≤14 d | 中重度肾功能损伤慎用 | |||
氢溴酸氘瑞米德韦(VV116)[ | 第1天:600 mg、1次/12 h,口服;第2~5天:300 mg、1次/12 h,口服 | 暂无研究数据 |
药物 | eGFR≥60 mL·min-1·(1.73 m2)-1 | eGFR 30~59 mL·min-1·(1.73 m2)-1 | eGFR 15~29 mL·min-1·(1.73 m2)-1 | eGFR<15 mL·min-1·(1.73 m2)-1 | 透析 |
---|---|---|---|---|---|
地塞米松 | 5 mg[ | 5 mg或6 mg、1次/d,口服/静脉推注/静脉滴注,谨慎使用3~5 d,最长不超过10 d,期间监测肾功能,注意继发感染 | |||
巴瑞替尼 | 4 mg、1次/d,口服[ | 2 mg、1次/d,口服[ | 2 mg、1次/48 h,口服[ | 不建议使用 | |
托珠单抗 | 8 mg/kg、1次/d,静脉滴注(静脉滴注持续1 h以上) |
Table 3 Dose adjustment table for drugs acting on inflammatory targets to treat COVID-19 infection inpatients with different kidney function levels
药物 | eGFR≥60 mL·min-1·(1.73 m2)-1 | eGFR 30~59 mL·min-1·(1.73 m2)-1 | eGFR 15~29 mL·min-1·(1.73 m2)-1 | eGFR<15 mL·min-1·(1.73 m2)-1 | 透析 |
---|---|---|---|---|---|
地塞米松 | 5 mg[ | 5 mg或6 mg、1次/d,口服/静脉推注/静脉滴注,谨慎使用3~5 d,最长不超过10 d,期间监测肾功能,注意继发感染 | |||
巴瑞替尼 | 4 mg、1次/d,口服[ | 2 mg、1次/d,口服[ | 2 mg、1次/48 h,口服[ | 不建议使用 | |
托珠单抗 | 8 mg/kg、1次/d,静脉滴注(静脉滴注持续1 h以上) |
分类 | CrCl≥30 mL/min | CrCl<30 mL/min |
---|---|---|
COVID-19重症患者 | ||
肝素抗凝 | 建议使用预防剂量抗凝药物,如依诺肝素40 mg/d[ | CrCl<30 mL/min时,预防剂量的依诺肝素应减量至30 mg/d;普通肝素无需调整[ |
阿司匹林或P2Y12抑制剂[ | 经验性予抗血小板药物无明确获益且出血风险增加,建议不新增使用 | |
COVID-19住院患者(非重症) | ||
肝素抗凝a | 建议使用治疗剂量的抗凝疗法。治疗剂量的抗凝治疗,如依诺肝素:1 mg/kg、2次/d[ | CrCl<30 mL/min时,治疗剂量的依诺肝素需减量至1 mg/kg、1次/d[ |
直接口服抗凝剂(如利伐沙班)[ | 在缺乏口服抗凝治疗指征的情况下,应避免使用治疗剂量的利伐沙班等直接口服抗凝药物 | |
阿司匹林[ | 经验性予抗血小板药物无明确获益且出血风险增加,建议不新增使用 | |
COVID-19感染门诊患者[ | 对于临床症状稳定的COVID-19感染门诊患者经验性使用阿哌沙班、阿司匹林没有明显获益,建议暂不新增使用 | |
出院患者[ | 存在高血栓风险但低出血风险者,口服利伐沙班10 mg/d预防血栓可能获益;暂无针对CKD的剂量调整数据 |
Table 4 Dose adjustment table of commonly used antithrombotic drugs for COVID-19 infection in patients with different kidney function levels
分类 | CrCl≥30 mL/min | CrCl<30 mL/min |
---|---|---|
COVID-19重症患者 | ||
肝素抗凝 | 建议使用预防剂量抗凝药物,如依诺肝素40 mg/d[ | CrCl<30 mL/min时,预防剂量的依诺肝素应减量至30 mg/d;普通肝素无需调整[ |
阿司匹林或P2Y12抑制剂[ | 经验性予抗血小板药物无明确获益且出血风险增加,建议不新增使用 | |
COVID-19住院患者(非重症) | ||
肝素抗凝a | 建议使用治疗剂量的抗凝疗法。治疗剂量的抗凝治疗,如依诺肝素:1 mg/kg、2次/d[ | CrCl<30 mL/min时,治疗剂量的依诺肝素需减量至1 mg/kg、1次/d[ |
直接口服抗凝剂(如利伐沙班)[ | 在缺乏口服抗凝治疗指征的情况下,应避免使用治疗剂量的利伐沙班等直接口服抗凝药物 | |
阿司匹林[ | 经验性予抗血小板药物无明确获益且出血风险增加,建议不新增使用 | |
COVID-19感染门诊患者[ | 对于临床症状稳定的COVID-19感染门诊患者经验性使用阿哌沙班、阿司匹林没有明显获益,建议暂不新增使用 | |
出院患者[ | 存在高血栓风险但低出血风险者,口服利伐沙班10 mg/d预防血栓可能获益;暂无针对CKD的剂量调整数据 |
项目 | eGFR≥60 mL·min-1·(1.73 m2)-1 | eGFR 30~59 mL·min-1·(1.73 m2)-1 | eGFR 15~29 mL·min-1·(1.73 m2)-1 | eGFR<15 mL·min-1·(1.73 m2)-1 | 透析 |
---|---|---|---|---|---|
安巴韦单抗/罗米司韦单抗注射液 | 安巴韦单抗注射液1 000 mg、罗米司韦单抗注射液1 000 mg静脉滴注序贯给药,病程中仅给药1次[ | CKD患者中理论上无需调整剂量,有待研究数据验证 | |||
静注COVID-19人免疫球蛋白 | 轻型100 mg/kg、中型200 mg/kg、重型400 mg/kg,静脉滴注,根据患者病情改善情况,次日可再次静脉滴注,总次数≤5次[ | CKD患者中理论上无需调整剂量,有待研究数据验证 | |||
康复者恢复期血浆 | 200~500 mL(4~5 mL/kg),病程中一般给药1次,可根据患者个体情况及病毒载量等决定是否再次静脉滴注[ | CKD患者中理论上无需调整剂量,有待研究数据验证 |
Table 5 Dose adjustment table of COVID-19 neutralizing antibodies in patients with different kidney function levels
项目 | eGFR≥60 mL·min-1·(1.73 m2)-1 | eGFR 30~59 mL·min-1·(1.73 m2)-1 | eGFR 15~29 mL·min-1·(1.73 m2)-1 | eGFR<15 mL·min-1·(1.73 m2)-1 | 透析 |
---|---|---|---|---|---|
安巴韦单抗/罗米司韦单抗注射液 | 安巴韦单抗注射液1 000 mg、罗米司韦单抗注射液1 000 mg静脉滴注序贯给药,病程中仅给药1次[ | CKD患者中理论上无需调整剂量,有待研究数据验证 | |||
静注COVID-19人免疫球蛋白 | 轻型100 mg/kg、中型200 mg/kg、重型400 mg/kg,静脉滴注,根据患者病情改善情况,次日可再次静脉滴注,总次数≤5次[ | CKD患者中理论上无需调整剂量,有待研究数据验证 | |||
康复者恢复期血浆 | 200~500 mL(4~5 mL/kg),病程中一般给药1次,可根据患者个体情况及病毒载量等决定是否再次静脉滴注[ | CKD患者中理论上无需调整剂量,有待研究数据验证 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
劳海燕,刘双信. 肾内科临床使用新冠防治药物的药学建议(临床版)[M].北京:人民卫生出版社,2022.
|
[8] |
新型冠状病毒感染诊疗方案(试行第十版)[EB/OL].(2023-01-05)[2023-02-17].
|
[9] |
希恩.C.斯威曼.马汀代尔药物大典(中文版)[M]. 35版.李大魁,金有豫,汤光,等译.北京:化学工业出版社,2009.
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
曹博,陈罡,陈昊,等. COVID-19治疗手册[M]. 8.1版.日本厚生省,2022.
|
[15] |
The ATTACC,ACTIV-4a,and REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19[J]. N Engl J Med,2021,385(9):777-789. DOI:10.1056/nejmoa2103417.
|
[16] |
|
[17] |
|
[18] |
REMAP-CAP Writing Committee for the REMAP-CAP Investigators,
|
[19] |
Recovery Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY):a randomised,controlled,open-label,platform trial[J]. Lancet,2022,399(10320):143-151. DOI:10.1016/S0140-6736(21)01825-0.
|
[20] |
Investigators The ATTACC ACTIV-a and REMAP-CAP. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19[J]. N Engl J Med,2021,385(9):790-802. DOI:10.1056/nejmoa2105911.
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
National Clinical Evidence Taskforce - COVID-19. Australian guidelines for the clinical care of people with COVID-19[EB/OL]. (2022-12-20)[2023-01-10].
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19:final results of the WHO Solidarity randomised trial and updated meta-analyses[J]. Lancet,2022,399(10339):1941-1953. DOI:10.1016/S0140-6736(22)00519-0.
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
US National Library of Medicine. ClinicalTrials.gov[EB/OL]. (2022-01-03)[2023-01-10].
|
[38] |
|
[39] |
US Food and Drug Administration. Fact sheet for healthcare providers:emergency use authorization for paxlovid[EB/OL]. (2022-09-26)[2023-01-10].
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[45] |
|
[46] |
|
[47] |
|
[48] |
|
[49] |
Recovery Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY):a randomised,controlled,open-label,platform trial and updated meta-analysis[J]. Lancet,2022,400(10349):359-368. DOI:10.1016/S0140-6736(22)01109-6.
|
[50] |
|
[51] |
|
[52] |
|
[53] |
|
[54] |
|
[55] |
|
[56] |
|
[57] |
|
[58] |
Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY):a randomised,controlled,open-label,platform trial[J]. Lancet,2021,397(10285):1637-1645. DOI:10.1016/S0140-6736(21)00676-0.
|
[59] |
|
[60] |
|
[61] |
|
[62] |
|
[63] |
American Society of Hematology. ASH clinical practice guidelines on venous thromboembolism[EB/OL]. (2022-06-24)[2023-01-10].
|
[64] |
National Institutes of Health. COVID-19 treatment guidelines:antithrombotic therapy in patients with COVID-19[EB/OL]. (2022-02-01)[2023-01-10].
|
[65] |
|
[66] |
|
[67] |
|
[68] |
|
[69] |
|
[70] |
|
[71] |
Intervention in COVID-19 linked hypercoaguable states characterized by circuit thrombosis utilizing a direct thrombin inhibitor[J]. Thrombosis Update,2020,1:100009.
|
[72] |
|
[73] |
|
[74] |
|
[75] |
|
[76] |
|
[77] |
US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA)of bamlanivimab and etesevimab[EB/OL]. (2022-01-24)[2023-01-10].
|
[78] |
US Food and Drug Administration. Fact sheet for healthcare providers emergency use authorization (EUA)of sotrovimab[EB/OL]. (2022-03-25)[2023-01-10].
|
[79] |
US Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA)of REGEN-COV[EB/OL]. (2022-01-24)[2023-01-10].
|
[1] | ZHANG Di, LI Hongpeng, MA Jiang, NIE Qian, SUN Jianfeng, WU Zhipeng, ZHANG Hongcai, ZHAO Jue. Effect of Ocular Acupuncture and Exercise Combination Therapy on Postoperative Heart Rate Variability and Prognosis of Patients Treated with Percutaneous Coronary Intervention [J]. Chinese General Practice, 2023, 26(36): 4535-4544. |
[2] | LIU Bingwei, WANG Jing, QIAO Xue, MU Silin, SHI Guangxi, LI Jingwei. Clinical Characteristics and Traditional Chinese Medicine of Hyperlipidemia in Estrogen Receptor Positive Breast Cancer Patients during Endocrine Therapy: a Real World Study [J]. Chinese General Practice, 2023, 26(36): 4558-4564. |
[3] | WEI Zongbo, LONG Bingcai, WANG Xiongjiang, LIANG Yingye, TANG Hongliang, XIA Tian, LU Dongming. Effect and Mechanism of Pivot Meridian Massage on TLR8/ERK Signaling Pathway and LncRNA-GAS5 in Rats with Neuropathic Pain [J]. Chinese General Practice, 2023, 26(36): 4565-4574. |
[4] | Eating Disorders Coordination Group of the Psychosomatic Medicine Society of the Chinese Medical Association, Eating Disorders Research Collaboration Group of the Psychiatric Medicine Society of the Chinese Medical Association, CHEN Yan, CHEN Han, LIU Lanying, KONG Qingmei, QIAO Huifen, ZHANG Lan, LI Xueni, KUANG Guifang, ZHANG Darong, LI Keqing, WANG Zhen, CHEN Jue. Chinese Expert Consensus on the Diagnosis and Treatment of Bulimia Nervosa [J]. Chinese General Practice, 2023, 26(36): 4487-4497. |
[5] | LIU Puqing, CHEN Jingwen, SHOU Zhangxuan. Evaluation of Potentially Inappropriate Medication of Direct Oral Anticoagulant in Hospitalized Elderly Patients with Non-valvular Atrial Fibrillation Based on Beers Criteria [J]. Chinese General Practice, 2023, 26(35): 4388-4393. |
[6] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[7] | XU Man, AN Zhuoling, ZHANG Yuhui, MA Zhuo. Current Situation of Potentially Inappropriate Medication in Older Cancer Patients and Strategies to Address It [J]. Chinese General Practice, 2023, 26(35): 4382-4387. |
[8] | Expert Consensus Writing Group of Integrated Traditional Chinese and Western Medicine Management for Chronic Obstructive Pulmonary Disease. Expert Consensus on Integrated Traditional Chinese and Western Medicine Management for Chronic Obstructive Pulmonary Disease (2023 Edition) [J]. Chinese General Practice, 2023, 26(35): 4359-4371. |
[9] | ZHANG Qian, LI Shu, LI Pengmei. Interpretation of the 2023 AGS Beers Criteria: Potentially Inappropriate Medication Use in Older Adults [J]. Chinese General Practice, 2023, 26(35): 4372-4381. |
[10] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[11] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[12] | SU Kaiqi, LYU Zhuan, WU Mingli, LUO Meng, GAO Jing, NIE Chenchen, LIU Hao, FENG Xiaodong. Effect of Electroacupuncture on BDNF/TrkB/PI3K/Akt Pathway and Hippocampal Neuronal Protection in Rats with Learning and Memory Impairment after Ischemia Reperfusion [J]. Chinese General Practice, 2023, 26(33): 4187-4193. |
[13] | LI Qianqian, CHEN Xunrui, ZHANG Wenying, YUAN Haihua, ZHANG Yanjie, JIANG Bin, LIU Feng. Demand and Influencing Factors for Community Health Services during Chemotherapy of Patients with Advanced Cancer [J]. Chinese General Practice, 2023, 26(33): 4173-4180. |
[14] | LU Guangqi, ZHUANG Minghui, ZHU Liguo, GAO Jinghua, WEI Xu, LI Luguang, YU Jie. Interpretation of Best Practices for Minimally Invasive Lumbar Spinal Stenosis Treatment 2.0 (MIST) : Consensus Guidance from the American Society of Pain and Neuroscience (ASPN) in 2022 [J]. Chinese General Practice, 2023, 26(32): 3995-4000. |
[15] | ZHANG Peng, GAO Ying, YANG Hongxi, WAN Chunxiao. Association between Serum Uric Acid Level and the Risk of Chronic Kidney Disease among the Elderly in Longevity Areas of China [J]. Chinese General Practice, 2023, 26(31): 3884-3889. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||